Key Influencing Factors Driving the Global Rare Disease Testing Market Through 2026

According to MarkNtel Advisors, the Global Rare Disease Testing Market is expected to witness around 9.29% CAGR during 2021-26. The market growth attributes primarily to the rising incidences of genetic disorders & different types of cancer, coupled with the evolution of direct-to-home genomic services and the introduction of big data in diagnosing rare diseases.

Market Report Coverage: Global Rare Disease Testing Market

Get a free report sample: https://www.marknteladvisors.com/query/request-sample/rare-disease-testing-market.html

Market Segmentation
1. By Type (Cardiovascular, Ophthalmological, Neurological, Oncological, Hematological, Endocrine and Metabolism, Gastroenterologist)
2. By Acquisition (Genetic, Externally Acquired)
3. By Technology (Next Generation Sequencing, Complete Genome, Complete Exome, Micro Arrays)
4. By Age Group (0-15 yrs., 16-30 yrs., 31-45 yrs.)
5. By Product (Kits & Assays, Panels)
6. By End User (Hospitals, Diagnostics Laboratories, Clinical Laboratories, Contract Research Organizations)

Region-wise Segmentation
• North America: US, Canada, Mexico
• South America: Brazil, Argentina
• Europe: The UK, Germany, France, Spain, Italy
• Asia-Pacific: China, India, Japan, Australia, Singapore
• Middle East & Africa: Israel, GCC

For more detailed analysis: https://www.marknteladvisors.com/research-library/rare-disease-testing-market.html

Key Growth Drivers
• Rising prevalence of genetic disorders
• Increasing research & development in the field of rare disease diagnostics
• Burgeoning awareness regarding treatment of rare diseases owing to various rare genome projects

Market Challenges
• Expensive sequencing procedures and their application in medical treatments
• Lack of awareness and long diagnostic delays
• Shortage of high-complexity testing centers

Share your requirements: https://www.marknteladvisors.com/query/request-customization/rare-disease-testing-market.html

Market Competitors:
Quest Diagnostics Inc., Centogene N.V., Invitae Corporation., 3billion, Inc., Arup Laboratories., Eurofins Scientific., Strand Life Sciences., Ambry Genetics., Color Genomics, Inc., Health Network Laboratories, PreventionGenetics, Progenity, Inc., Myriad Genetics, Inc., Laboratory Corporation of America Holdings, and OPKO Health, Inc.

Key Questions Answered in this Report:
1. What are the current & future trends in the Global Rare Disease Testing Market?
2. What are the overall statistics or estimates (Overview, Size- by Value, Forecast Numbers, Segmentation, and Shares) of the Global Rare Disease Testing Market?
3. How has the industry been evolving in terms of geography & service adoption?
4. How has the competition been shaping across the globe, followed by their comparative factorial indexing?
5. What are the key growth drivers & challenges for the Global Rare Disease Testing Market?
6. What are the customer orientation, purchase behavior, and expectations from Rare Disease Testing providers across the globe?
7. What are the region-wise industry size, growth drivers, and challenges?
8. What are the key innovations, opportunities, current & future trends, and regulations in the Global Rare Disease Testing Market?
9. Who are the key competitors, their key strengths & weaknesses, and how do they perform in the Global Rare Disease Testing Market based on a competitive benchmarking matrix?
10. What are the key results derived from the surveys conducted during the Global Rare Disease Testing Market study?

MarkNtel Advisors
1147 88AVE, Delta, British Columbia, BC,V4C,3B8, CANADA
Email: sales@marknteladvisors.com
Tel: +1 604 800 2671
Website: https://www.marknteladvisors.com

About us:
MarkNtel Advisors is a leading research, consulting and data analytics firm that provides a wide range of strategic reports on diverse industry verticals to a substantial and varied client base that includes multinational corporations, financial institutions, governments, and individuals.

We specialize in niche industries and emerging geographies to support our clients in the formulation of strategies viz. Go to Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, trend analysis, etc. in around 15 industry verticals to enable our clients in identifying attractive investment opportunities and maximizing ROI through an early mover advantage.

This release was published on openPR.